… to the effectiveness of lysate-pulsed DC vaccines. For instance, … In a phase I study, advanced
melanoma patients were … with total RNA of colorectal cancer cells previously submitted to …

… lysate-pulsed DCs vaccine as intradermal injections in the … of 5 patients with stage D 3
patients advanced to stage B and … Dendritic cell vaccination for metastatic melanoma: a 14-year …

… in CRC cell lysate-pulsed-DCs via transfection of siRNA to enhance the efficacy of DC-based …
Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the …

… dendritic cells for autologous therapeutic cancer vaccines. We … Two of them had refractory
colorectal cancer (CRC), and one … CTLA4 blockade in patients with metastatic melanoma. Clin …

… are approved for regionally metastatic colorectal cancer but have … studies, the DC-based
vaccine is one of the safe cancer … exhibited greater in vivo protection against melanoma than …

… -derived and tumor lysate-pulsed mature DC-based vaccine (APCEDEN … phase 3 study is
currently evaluating active immunization in adjuvant therapy of patients with stage 3 melanoma …

… patients in an advanced disease stage often included the use of cytokines (ie, IFN, IL-2),
adoptive cell therapy and DC-based vaccines, … in patients with metastatic melanoma [71] and …

… of dendritic cell vaccines in different solid tumors regarding … year, colorectal cancer (CRC)
is the second leading cause of … were feasible and safe in advanced melanoma patients [35]. …

… the foundation of a phase I study for the treatment of metastatic melanoma in which a 3D …
an autologous tumour lysate is implanted in patients with melanoma (NCT01753089). For 3D …

… The most convincing serologic data for desirable immune responses in our cancer trials
came from the melanoma randomized trial in which there were obvious changes in clusters of …